Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

735
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
735
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

489
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
489
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TaILOR: a randomised trial to compare the clinical and cost-effectiveness of a patient-initiated follow-up (PIFU) strategy compared to standard care pathways in people with inflammatory arthritis: a study protocol.

Trials·2026
Same author

Association between SARS-CoV-2 booster vaccination and hospitalisation and/or death due to COVID-19 in adults with immune-mediated inflammatory diseases: nested case-control study using linked primary-care, hospitalisation and mortality data from England.

RMD open·2026
Same author

The OMERACT core domain sets for calcium pyrophosphate deposition disease.

Seminars in arthritis and rheumatism·2026
Same author

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).

Annals of the rheumatic diseases·2026
Same author

Retrospective Assignment to Study Groups Lowers More Than Urate Levels.

JAMA internal medicine·2026
Same author

OA fundamentals series: Diagnosis and clinical assessment of osteoarthritis.

Osteoarthritis and cartilage·2026

Related Experiment Video

Updated: Feb 16, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

767

New urate-lowing therapies.

Abhishek Abhishek1

  • 1Division of Rheumatology, Orthopaedics, and Dermatology, School of Medicine, University of Nottingham, Nottingham, UK.

Current Opinion in Rheumatology
|December 19, 2017
PubMed
Summary

Lesinurad and arhalofenate are novel drugs for gout treatment. Lesinurad, used with xanthine oxidase inhibitors, helps lower uric acid, while arhalofenate offers anti-inflammatory effects.

Area of Science:

  • Pharmacology
  • Nephrology
  • Rheumatology

Background:

  • Gout management often requires lowering serum uric acid levels.
  • Xanthine oxidase inhibitors (XOIs) are standard treatments, but some patients need additional options.
  • Novel therapeutic agents are being investigated to improve gout treatment outcomes.

Purpose of the Study:

  • To review recent studies on lesinurad and arhalofenate for gout treatment.
  • To discuss the mechanisms of action, efficacy, and safety profiles of these agents.

Main Methods:

  • Review of recent clinical studies and pharmacological data.
  • Analysis of drug interactions and patient populations.
  • Evaluation of urate-lowering and anti-inflammatory effects.

More Related Videos

Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

6.3K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.0K

Related Experiment Videos

Last Updated: Feb 16, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

767
Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

6.3K
Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

2.0K

Main Results:

  • Lesinurad inhibits URAT-1 and OAT-4, lowering uric acid, particularly when combined with XOIs.
  • Lesinurad's efficacy is reduced in patients with eGFR < 30 mL/min.
  • Arhalofenate inhibits URAT-1 and the NALP-3 inflammasome, offering anti-inflammatory benefits.
  • Arhalofenate has a weaker urate-lowering effect than lesinurad.

Conclusions:

  • Lesinurad offers an additional treatment option for gout patients who do not achieve target serum uric acid levels with XOIs alone.
  • Arhalofenate shows promise for gout treatment due to its dual urate-lowering and anti-inflammatory properties, pending further evaluation.
  • Both agents require careful consideration of renal function and potential drug interactions.